Bruker Executive and Leadership Team

Frank Laukien, the Chairman, President & Chief Executive Officer at Bruker, directs the overarching strategic vision for the global scientific instrumentation portfolio. Overseeing the integration of mass spectrometry, magnetic resonance, and advanced spectroscopy systems, the Chairman, President & Chief Executive Officer ensures alignment between research initiatives and commercial market demands. This leadership role involves managing complex international operations across the Americas, EMEA, and Asia-Pacific regions to maintain a competitive edge in the semiconductor and biotechnology sectors. By prioritizing innovation in atomic force microscopy and radiological detection, Frank Laukien drives the long-term growth trajectory of the organization. Laukien maintains rigorous standards for operational efficiency while fostering partnerships with academic and government institutions. Through consistent focus on high-performance materials and diagnostic technologies, the Chief Executive Officer secures the market position of the company as a premier provider of analytical tools for critical scientific research and industrial applications.

Gerald Herman, the Executive VP & Chief Financial Officer at Bruker, manages the global financial architecture and capital allocation strategies for the entire organization. Overseeing fiscal planning, investor relations, and corporate reporting, the Executive VP & Chief Financial Officer ensures the financial health required to support extensive R&D in mass spectrometry and superconducting materials. This leadership role involves optimizing cost structures across diverse manufacturing segments to maximize shareholder value while funding expansion into emerging diagnostic markets. By implementing robust financial controls, Gerald Herman directly impacts the ability of the company to scale production of handheld X-ray fluorescence devices and semiconductor metrology equipment. Herman coordinates with the Board to evaluate acquisition opportunities and capital investments that strengthen the global footprint. Through disciplined oversight of liquidity and risk management, the Chief Financial Officer sustains the operational stability necessary for the company to deliver cutting-edge scientific solutions to customers worldwide.

Mark Munch, the President, Bruker BNANO Group at Bruker, architects the development and commercialization of advanced nanotechnology and semiconductor metrology solutions. Overseeing the engineering and production of atomic force microscopy and defect-detection systems, the President, Bruker BNANO Group ensures that the product portfolio meets the rigorous precision requirements of the global semiconductor industry. This leadership role involves driving technical innovation to support advancements in materials science and nanotechnology research across North American and international markets. By aligning product development with the evolving needs of high-tech manufacturing, Mark Munch directly influences the competitive standing of the company in the nano-analysis space. Munch collaborates with cross-functional teams to accelerate the deployment of next-generation metrology tools that enhance yield and quality for industrial clients. Through strategic focus on high-performance instrumentation, the President of the BNANO Group enables breakthroughs in research and industrial process control for customers in the semiconductor and materials sectors.

Bryce McEuen, the President, Bruker Biomedical Systems at Bruker, directs the strategic growth and operational execution of the biomedical instrumentation division. Overseeing the development of fluorescence optical microscopy and diagnostic technologies, the President, Bruker Biomedical Systems ensures that the company provides essential tools for biotechnology, clinical laboratories, and pharmaceutical research. This leadership role involves expanding the reach of diagnostic solutions across global healthcare markets to improve clinical outcomes and research efficiency. By optimizing the product lifecycle for complex imaging and diagnostic systems, Bryce McEuen directly supports the mission of the company to provide high-performance solutions for life science applications. McEuen coordinates with internal research teams to integrate new optical technologies into the existing portfolio, ensuring relevance in a rapidly changing clinical landscape. Through dedicated management of the biomedical segment, the President of Biomedical Systems drives revenue growth and strengthens the reputation of the company as a leader in clinical and research-grade diagnostic instrumentation.